These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 8629676)

  • 41. [Hemochromatosis associated with hereditary spherocytosis].
    López DE; Kohan M; Ferreño D; Raffa MP; Prytyka A
    Acta Gastroenterol Latinoam; 1997; 27(4):267-70. PubMed ID: 9580054
    [TBL] [Abstract][Full Text] [Related]  

  • 42. End stage liver disease in a 13-year old secondary to hepatitis C and hemochromatosis.
    Miller M; Crippin JS; Klintmalm G
    Am J Gastroenterol; 1996 Jul; 91(7):1427-9. PubMed ID: 8678008
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Deferoxamine prevents cardiac hypertrophy and failure in the gerbil model of iron-induced cardiomyopathy.
    Yang T; Brittenham GM; Dong WQ; Levy MN; Obejero-Paz CA; Kuryshev YA; Brown AM
    J Lab Clin Med; 2003 Nov; 142(5):332-40. PubMed ID: 14647037
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Intensifying iron chelating therapy with desferrioxamine using implantable venous access catheters (Port-A-Cath)].
    de Montalembert M; Jan D; Clairicia M; Hannedouche T; Sidi D; Girot R
    Arch Fr Pediatr; 1992 Mar; 49(3):159-63. PubMed ID: 1610270
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Effect of deferoxamine on erythropoiesis in patients hemodialyzed for chronic renal insufficiency treated with erythropoietin].
    Kalinowski M; Popławski A; Kaliszewski Z; Juzwiuk J
    Pol Merkur Lekarski; 1996 Oct; 1(4):232-4. PubMed ID: 9156931
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Treatment of primary idiopathic hemochromatosis and secondary hemosiderosis].
    Strohmeyer G
    Dtsch Med Wochenschr; 1974 Nov; 99(45):2295-9. PubMed ID: 4448138
    [No Abstract]   [Full Text] [Related]  

  • 47. Desferal therapy in iron storage disease.
    Thompson RB; Owen DM; Bell WN
    Am J Med Sci; 1967 Apr; 253(4):453-60. PubMed ID: 6021380
    [No Abstract]   [Full Text] [Related]  

  • 48. [First results of a new iron chelating agent in the treatment of post-transfusional hemochromatosis].
    Giraud P; Orsini A; Giraud F; Pinsard N
    Arch Fr Pediatr; 1965 Apr; 22(4):463-8. PubMed ID: 5826583
    [No Abstract]   [Full Text] [Related]  

  • 49. The use of peritoneal dialysis in special situations.
    Swartz RD
    Adv Perit Dial; 1999; 15():160-6. PubMed ID: 10682094
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Medical and surgical treatment of neonatal hemochromatosis: single center experience.
    Heffron T; Pillen T; Welch D; Asolati M; Smallwood G; Hagedorn P; Fasola C; Solis D; Rodrigues J; DePaolo J; Spivey J; Martinez E; Henry S; Romero R
    Pediatr Transplant; 2007 Jun; 11(4):374-8. PubMed ID: 17493216
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Continuous subcutaneous desferrioxamine injection in primary idiopathic hemochromatosis with macrocytic anemia].
    Schneider C; Richter H; Fischer JL; Larcher W
    Internist (Berl); 1989 May; 30(5):335-7. PubMed ID: 2661477
    [No Abstract]   [Full Text] [Related]  

  • 52. [Mechanism of action of desferrioxamine].
    Kaszewska-Jablońska I; Zielińska W
    Wiad Lek; 1975 Jan; 28(2):89-96. PubMed ID: 1111247
    [No Abstract]   [Full Text] [Related]  

  • 53. Intraperitoneal deferoxamine therapy for iron overload in children undergoing CAPD.
    Andreoli SP; Cohen M
    Kidney Int; 1989 Jun; 35(6):1330-5. PubMed ID: 2770113
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Iron overload in congenital erythrocyte pyruvate kinase deficiency.
    Salem HH; Van Der Weyden MB; Firkin BG
    Med J Aust; 1980 May; 1(11):531-2. PubMed ID: 7393032
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Hyperpigmentation and secondary hemochromatosis: a novel treatment with extracorporeal chelation.
    Held JL; Yankiver B; Kohn SR
    J Am Acad Dermatol; 1993 Feb; 28(2 Pt 1):253-4. PubMed ID: 8432923
    [No Abstract]   [Full Text] [Related]  

  • 56. Reversion of age-related recognition memory impairment by iron chelation in rats.
    de Lima MN; Dias CP; Torres JP; Dornelles A; Garcia VA; Scalco FS; Guimarães MR; Petry RC; Bromberg E; Constantino L; Budni P; Dal-Pizzol F; Schröder N
    Neurobiol Aging; 2008 Jul; 29(7):1052-9. PubMed ID: 17346856
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Use of bolus intraperitoneal iron dextran in continuous ambulatory peritoneal dialysis or continuous cyclic peritoneal dialysis patients receiving recombinant human erythropoietin.
    Mars RL; Moles K; Pope K; Hargrove P
    Adv Perit Dial; 1999; 15():60-4. PubMed ID: 10682073
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Therapeutic management of neonatal hemochromatosis: report of four cases and literature review.
    Annagür A; Altunhan H; Yüksekkaya HA; Örs R
    Hum Exp Toxicol; 2011 Oct; 30(10):1728-34. PubMed ID: 21247995
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparing Care of the Primary and Secondary Hemochromatosis Patients.
    Becker S
    J Infus Nurs; 2020; 43(2):65-69. PubMed ID: 32106193
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical aspects of hemochromatosis.
    O'Neil J; Powell L
    Semin Liver Dis; 2005 Nov; 25(4):381-91. PubMed ID: 16315132
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.